- Company-wide research offers novel pathways for enhancing
kidney patient care using data-driven insights and real-world
evidence
WALTHAM,
Mass., Oct. 31, 2023 /PRNewswire/ -- Fresenius
Medical Care, the world's leading provider of products and services
for individuals with renal diseases, today announced the
presentation of over 60 company-affiliated research abstracts at
the American Society of Nephrology's (ASN) Kidney Week 2023 taking
place November 2-5 in
Philadelphia.
Fresenius Medical Care announces
presentations at the American Society of Nephrology (ASN) Kidney
Week 2023.
"The scientific and medical breadth of research presented this
year highlights the power of Fresenius Medical Care's global scope
and scale in creating data-driven insights that have the potential
to improve patient care and outcomes," said Dr. Frank Maddux, Global Chief Medical Officer and
Member of the Management Board for Fresenius Medical Care. "Our
presentations cover key topics including advances in machine
learning and artificial intelligence in kidney care, using big data
and real-world evidence to drive insights, advancing home dialysis,
and research around hemodiafiltration (HDF) and hemodialysis (HD)
therapies. We look forward to sharing our insights at this year's
conference."
Scientific and medical experts from across Fresenius Medical
Care will present research related to many important topics in
kidney disease care. A link to all Fresenius Medical
Care-affiliated presentations can be found on our company's
website: https://fmcna.com/ASN-2023/. Highlights of this year's
presentations for the medical congress include:
- Artificial Intelligence and Data Science:
- Impact of Nationwide Utilization of a Machine Learning Model to
Identify Home Therapy Candidates (November
2, 10:00 AM – 12:00 PM): Education on a machine learning
predictive model which identifies in-center hemodialysis patients
who would be good candidates for home therapy.
- Comparative Prognostic Accuracy of Vascular Access Flow and
Artificial Intelligence (AI)-Based Arteriovenous Fistula (AVF)
Failure Risk Score (November 3,
10:00 AM – 12:00 PM): Presenting a risk score which
accurately and reproducibly predicts AVF failure within 3 months
that may offer a cheaper and automated alternative to Qa
measurement.
- Data-Driven Global Insights:
- Apollo DB: Characteristics of a Global Dialysis Database Across
Major World Regions (November 2,
10:00 AM – 12;00 PM): Capturing data
from over 40 countries, Apollo DB is an anonymized dialysis
database that combines and harmonizes data from a global provider
for research and quality improvement activities.
- Characteristics of Global Dialysis Data from Multiple Providers
in the New MONitoring Dialysis Outcomes (MONDO) Dataset
(November 2, 10:00 AM – 12:00
PM): Research captured from 20 years of longitudinal patient
data contributed to the new MONDO dataset, the most robust global
dialysis dataset in the world.
- Creatinine Clearance Predicts Longitudinal Phosphate Levels
Irrespective of Achieved Urea Kt/V: A Peritoneal Dialysis-MONDO
Analysis (November 4, 10:00 AM – 12:00
PM): Experts present a study designed to evaluate if CrCl
predicts longitudinal PO4 irrespective of achieved Kt/V.
- Hemodiafiltration (HDF) and Hemodialysis (HD) Research:
- Relative Blood Volume Monitoring Using Crit-Line and
Hospital Admissions: A Retrospective Analysis of over 25,000
Patients Across 330 Dialysis Clinics (November 2, 10:00
AM – 12:00 PM): Presenting a
comparison of hospital admissions among Fresenius Kidney Care (FKC)
clinics with high utilization of RBV and propensity score matched
(PSM) clinics not using RBV.
- Real-World Effectiveness of Hemodialysis Modalities
(November 2, 10:00 AM – 12:00
PM): A late-breaking abstract that provides real world
evidence demonstrating comparison of patients treated with
hemodialysis vs hemodiafiltration.
- Dialyzer Performance and Associations in Self-Reported Pruritis
and Fatigue: Results from the eMPORA III Trial (November 3, 10:00
AM – 12:00 PM): eMPORA III was
a multi-center crossover trial with 4-week randomized treatment
periods comparing dialyzer performance (FX CorAL 600 vs two
comparable high-flux dialyzers) in post-dilution online
hemodiafiltration (HDF).
- Psychometric Validation of the CONVINCE Inter-
and Intradialytic Symptoms Questionnaire (November 3, 10:00
AM – 12:00 PM): The CONVINCE
Scientific Committee and CONVINCE Investigators present the survey
developed based on the KDQOL symptoms scale with an adapted recall
period of 7 days for interdialytic symptoms and extended inter- and
intradialytic (IDS) items based on literature review and patient
interviews.
Fresenius Medical Care is the world's leading provider of
products and services for individuals with renal diseases of which
around 3.9 million patients worldwide regularly undergo dialysis
treatment. Through its network of 4,050 dialysis clinics, Fresenius
Medical Care provides dialysis treatments for approximately 344,000
patients around the globe. Fresenius Medical Care is also the
leading provider of dialysis products such as dialysis machines or
dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock
Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company's website at
www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject
to various risks and uncertainties. Actual results could differ
materially from those described in these forward-looking statements
due to various factors, including, but not limited to, changes in
business, economic and competitive conditions, legal changes,
regulatory approvals, impacts related to the COVID-19 pandemic
results of clinical studies, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties
are detailed in Fresenius Medical Care AG & Co. KGaA's reports
filed with the U.S. Securities and Exchange Commission. Fresenius
Medical Care AG & Co. KGaA does not undertake any
responsibility to update the forward-looking statements in this
release.
Media Contact
Ryan Jimenez
T +1 800 723-2384
media@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609-2601
dominik.heger@fmc-ag.com
www.freseniusmedicalcare.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-demonstrates-commitment-to-innovating-dialysis-and-kidney-disease-care-with-presentations-at-the-american-society-of-nephrology-asn-kidney-week-2023-301972698.html
SOURCE Fresenius Medical Care Holdings, Inc.
